INKTのROE（自己資本利益率）は？

Mink Therapeutics IncのROEは98.30%です。

INKTの配当利回りは？

Mink Therapeutics Incの配当利回りは0.00%です。

INKTの品質スコア（Quality Score）は？

当社のAIはINKTの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

INKTは今が買い時ですか？

当社AIのタイミングスコアは100点中51点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

INKTはどのセクターに属しますか？

Mink Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

INKT (NASDAQ) 株価分析 | MINK THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

INKT AI Analysis Summary

Our AI summary for INKT: Mink Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 98.30%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 51/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

INKT

Mink Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 65

USD 11.70

0.63 (5.69%) Day Change

Watchlist Portfolio Compare Chart

-1.82

D/E

98.3%

ROE

-120.2%

ROA

0.00%

Div Yield

MINK THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 11.70 Price 0.63 (5.69%) Day Change	NEWS SCORE: 65

INKT, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROAが低い
ROEの伸びが低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	65
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	11.70
PBV / Sector	-4.20 / 44,105.10
Earning Per Share	-2.74

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.13 M GREAT
Average 1W Daily Value	0.09 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	-1.03 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-120.17 / 185,260.64
ROA Average (%) / Sector	-204.03 / 36,684.64
ROA Change Average (%) / Sector	50.03 / 422,221.42 GREAT
ROE (%) / Sector	98.30 / 243,761.81 GREAT
ROE Average (%) / Sector	1,468.13 / 48,758.38
ROE Change Average (%) / Sector	-20.63 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

登録情報

Analyze Date	2026-08-06 08:00:10
Symbol	INKT
Name	MINK THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	4.98 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	53.26 / 9,702.21

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 149 Fifth Avenue, New York, NY, United States, 10010

Phone: 212 994 8250

Website: https://minktherapeutics.com

Sector: Healthcare >> Biotechnology

Description: MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.